Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy January 9, 2023May 23, 2023
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study October 27, 2020August 16, 2022
Alterity Therapeutics commences US investor meetings following positive clinical data May 13, 2019August 16, 2022
